|
業務類別
|
Biotechnology |
|
業務概覽
|
Nektar Therapeutics is a clinical-stage, research-based biopharmaceutical company headquartered in San Francisco, California, and incorporated in Delaware, focused on discovering and developing medicines in the field of immunotherapy. The Company directs its efforts toward creating immunomodulatory agents that selectively induce, amplify, attenuate, or prevent immune responses to achieve desired therapeutic outcomes. Its pipeline of clinical-stage and preclinical-stage immunomodulatory agents targets the treatment of autoimmune diseases, including rezpegaldesleukin, NKTR-0165, NKTR-0166, and NKTR-422, as well as cancer, including NKTR-255. |
| 公司地址
| 455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158 |
| 電話號碼
| +1 415 482-5300 |
| 傳真號碼
| +1 415 339-5300 |
| 公司網頁
| https://www.nektar.com |
| 員工數量
| 63 |
| Mr. Howard W. Robin |
Director, President and Chief Executive Officer |
美元 1.11M |
24/04/2026 |
| Ms. Linda Rubinstein |
Interim Chief Financial Officer and Principal accounting officer |
-- |
08/05/2026 |
| Dr. Jonathan Zalevsky, PhD |
Senior Vice President and Chief Research and Development Officer |
美元 717.56K |
13/03/2026 |
| Ms. Elizabeth Zhang |
Vice President, Legal and Corporate Counsel |
-- |
24/04/2026 |
|
|
| Mr. Howard W. Robin |
Director, President and Chief Executive Officer |
24/04/2026 |
| Mr. R. Scott Greer |
Independent Director |
24/04/2026 |
| Mr. Robert B. Chess |
Chairman of the Board |
24/04/2026 |
| Mr. Roy A. Whitfield |
Lead Independent Director |
24/04/2026 |
| Mr. Jeffrey R. Ajer |
Independent Director |
24/04/2026 |
| Dr. Diana M. Brainard, M.D. |
Independent Director |
24/04/2026 |
|
|
|
|
